



Prior Authorization Approval Criteria

Silenor (doxepin)

Generic name:	doxepin
Brand name:	Silenor
Medication class:	tricyclic antidepressant
FDA-approved uses:	Treatment of insomnia, characterized by difficulties with sleep maintenance.
Available dosage forms:	3 mg and 6 mg tablets
Usual dose:	3-6mg taken 30 minutes before bedtime. 3 mg is recommended for the elderly. Should not be taken within 3 hours of a meal.
Approximate monthly cost: (based on AWP 2011)	\$181.80/ month
Duration of therapy:	Indefinite

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Clinically diagnosed insomnia.
- Treatment failure on one of these products (oxazepam, temazepam, lorazepam, alprazolam, diazepam, flurazepam, trazodone).
- Treatment failure on Ambien.
- Underlying physical or psychological conditions (including addiction, depression, anxiety, sleep apnea, restless leg syndrome, circadian issues, pain, GERD, etc.) have been ruled out or are being adequately treated.
- Failed/intolerant to Doxepin concentrate.

Contraindication:

- Hypersensitivity to doxepin, any of its inactive ingredients, or other dibenzoxepines.
- Co-administration with monoamine oxidase inhibitors (MAOIs).
- Individuals with untreated narrow angle glaucoma.
- Individuals with severe urinary retention.

Not approved if:

- Does not meet the above-stated criteria.
- Have any contraindications to the use of doxepin.

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 3/09/11